Comparative Pharmacology
Head-to-head clinical analysis: ATACAND HCT versus TRICHLORMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATACAND HCT versus TRICHLORMETHIAZIDE.
ATACAND HCT vs TRICHLORMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
2-4 mg orally once daily; maximum 4 mg/day.
None Documented
None Documented
Clinical Note
moderateTrichlormethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digoxin."
Clinical Note
moderateTrichlormethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digitoxin."
Clinical Note
moderateTrichlormethiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Deslanoside."
Clinical Note
moderateCandesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Terminal elimination half-life is approximately 2-6 hours (average 3.5 h); clinical context: short half-life necessitates once or twice daily dosing for sustained diuresis.
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Primarily renal (tubular secretion); ~70% excreted unchanged in urine; minor biliary/fecal (<10% total).
Category C
Category C
Angiotensin II Receptor Blocker / Thiazide Diuretic
Thiazide Diuretic
Trichlormethiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Acetyldigitoxin."